Breaking News

UK’s Innovation Agency Backs Plasticell

Cell therapy producer will make red blood cell substitute from pluripotent stem cells

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has secured Biomedical Catalyst funding of over £920,000 from Innovate UK to create a safe, effective red blood cell substitute for human clinical transfusion, in collaboration with stem cell scientists at the University of Edinburgh. Over 90 million blood transfusions are carried out worldwide each year and alternative sources to donor-derived blood are being sought to meet rising demand. In additio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters